

(19)



Europäisches Patentamt

European Patent Office

Office européen des brevets



(11) EP 0 956 862 A1

(12)

## EUROPEAN PATENT APPLICATION

(43) Date of publication:

17.11.1999 Bulletin 1999/46

(51) Int. Cl.<sup>6</sup>: A61K 38/22, C07K 14/575

(21) Application number: 98119160.4

(22) Date of filing: 04.11.1996

(84) Designated Contracting States:

AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC  
NL PT SE

Designated Extension States:

AL LT LV RO SI

(30) Priority: 22.11.1995 US 561732

(62) Document number(s) of the earlier application(s) in accordance with Art. 76 EPC:  
96938773.7 / 0 866 720

(71) Applicant: AMGEN INC.  
Thousand Oaks California 91320 -1789 (US)

(72) Inventors:

- Pelleymounter, Mary Ann  
San Dieg, CA 92130-1867 (US)

- Toombs, Christopher Francis  
Camarillo, CA 93012 (US)
- Mann, Michael Benjamin  
Thousand Oaks, CA 91360 (US)

(74) Representative:

Brown, John David et al  
FORRESTER & BOEHMERT  
Franz-Joseph-Strasse 38  
80801 München (DE)

### Remarks:

- This application was filed on 09 - 10 - 1998 as a divisional application to the application mentioned under INID code 62.
- The applicant has subsequently filed a sequence listing and declared, that it includes no new matter.

### (54) Methods of increasing lean tissue mass using ob protein compositions

(57) Methods of using OB protein compositions for increasing lean tissue mass are provided. Also provided are methods of using OB protein compositions for increasing insulin sensitivity, as well as increasing overall body strength and decreasing bone resorption. Furthermore fusion proteins comprising a Fc protein and an OB protein are provided.

EP 0 956 862 A1

**Description****FIELD OF THE INVENTION**

5 [0001] The present invention relates to methods of using OB protein compositions for increasing lean tissue mass.

**BACKGROUND**

10 [0002] Although the molecular basis for obesity is largely unknown, the identification of the "OB gene" and protein encoded ("OB protein") has shed some light on mechanisms the body uses to regulate body fat deposition. Zhang et al., *Nature* 372: 425-432 (1994); see also, the Correction at *Nature* 374: 479 (1995). The OB protein is active *in vivo* in both ob/ob mutant mice (mice obese due to a defect in the production of the OB gene product) as well as in normal, wild type mice. The biological activity manifests itself in, among other things, weight loss. See generally, Barinaga, "Obese" Protein Slims Mice, *Science* 269: 475-476 (1995).

15 [0003] The other biological effects of OB protein are not well characterized. It is known, for instance, that in ob/ob mutant mice, administration of OB protein results in a decrease in serum insulin levels, and serum glucose levels. It is also known that administration of OB protein results in a decrease in body fat. This was observed in both ob/ob mutant mice, as well as non-obese normal mice. Pelleymounter et al., *Science* 269: 540-543 (1995); Halaas et al., *Science* 269: 543-546 (1995). See also, Campfield et al., *Science* 269: 546-549 (1995)(Peripheral and central administration of 20 microgram doses of OB protein reduced food intake and body weight of ob/ob and diet-induced obese mice but not in db/db obese mice.) In none of these reports have toxicities been observed, even at the highest doses.

[0004] The elucidation of other biological effects of the OB protein, particularly on animals which may not benefit from or may not need weight reduction, will provide additional uses for the OB protein.

[0005] One such use, as provided by the present invention, is in the increase in lean tissue mass.

25 [0006] Of course, modulation of diet and exercise is one way to increase muscle size. There are also compositions used to increase lean mass. Current compositions thought to increase lean tissue mass include anabolic steroids, such as testosterone and derivatives, and human growth hormone. These are noted to have undesirable side effects however. (The summary below is fully explained in Remington's Pharmaceutical Sciences, 18th Ed. (1990, Mack Publishing Co., Easton, PA 18042) Chapter 50, at pages 948-1001.))

30 [0007] Human growth hormone, such as Protropin and Somatropin are noted to frequently cause hypercalciuria, which usually regresses in 2 to 3 months. Hyperglycemia and frank diabetes mellitus are also noted to occur. Myalgia and early morning headaches are noted to be relatively frequent, and occasionally cases of hypothyroidism and supersaturation of cholesterol in bile may occur. If the epiphyses are closed, the hormone should not be used because continued stimulation of growth of the phalanges and jawbone, but not other bones, can cause abnormal body proportions.

35 [0008] Anabolic steroids increase athletic performance and aggressiveness. Their use has been condemned by the American College of Sports Medicine. Female performance is improved, but at the expense of virilization and acne vulgaris. Androgens cause hirsutism, deepening or hoarseness of the voice, precocious puberty and epiphyseal closure in immature males, increased libido (in both male and female) priapism, oligospermia, and testicular atrophy, enlargement of the clitoris in the female, flushing, decreased ejaculatory volume and sperm population, gynecomastia, hypersensitivity, acne, weight gain, edema and hypercalcemia. Prolonged use increases aggressiveness, sometimes enormously, and many assaults are stated to be attributable to androgen abuse. Paranoia-like and other psychotic behavior has been reported. Biliary stasis and jaundice occur. There have been a few cases reported of hepatoma following long term therapy.

40 [0009] It is therefore desirable to have a therapeutic or cosmetic composition which increases lean tissue mass without side effects seen in the presently available drugs.

**SUMMARY OF THE INVENTION**

45 [0010] The present invention stems from the observation that administration of OB protein to non-obese as well as obese animals results in an increase of lean tissue mass. Thus, OB protein has the capacity to act, in addition to acting as a weight reducing agent, as an agent affecting lean tissue mass. As such, numerous lean tissue-mass increasing therapies are contemplated, even for patients who would not necessarily benefit from weight reduction. Thus, one aspect of the present invention is the use of OB protein (or analogs or derivatives thereof) for increasing lean tissue mass.

50 [0011] In another aspect, the present invention relates to methods of treating diabetes, and reducing the levels of insulin necessary for the treatment of diabetes. The increase in lean tissue mass, with concomitant decrease in fat tissue mass, increases sensitivity to insulin. Therefore, the present methods relate to use of OB protein (or analogs or derivatives thereof) for decreasing the amount of insulin necessary for the treatment of diabetes.

DETAILED DESCRIPTION

[0012] As stated above, the methods of the present invention are those for increasing lean tissue mass in an individual. This increase in lean tissue mass has been observed to accompany a decrease in fat mass. Thus, even if administration of OB protein (or analogs or derivatives thereof) does not result in a desired amount of weight loss, administration of OB protein may be useful to reconfigure body mass in reducing body fat, while increasing lean mass.

[0013] Additionally, the increase in lean tissue mass may make an individual more sensitive to insulin, and thus the present methods of using OB protein (or analogs or derivatives thereof) are also related to increasing insulin sensitivity in a diabetic patient. While the precise mode of action is uncertain, lean tissue (e.g., muscle), as compared to fat tissue,

10 may be more sensitive to the effects of insulin. Therefore, an increase in lean tissue may make available more cells which are sensitive to insulin. Further, elimination of fat (e.g., adipose) tissue may have the additional benefit of providing lean tissue with additional exposure to the peripheral circulation, where circulating insulin is found. It is therefore another aspect of the present invention that a method of increasing sensitivity to insulin is provided. Put another way, a method of decreasing the dosage of insulin needed by a diabetic is thus also provided.

15 [0014] The increase in lean tissue may be an increase in muscle tissue. Such increase is observed to be an overall increase, rather than localized to particular areas (e.g., Examples 1 and 2 below). As such, overall strength may increase. With the increase in overall strength, other benefits may result, such as a decrease in bone resorption, with the potential to reverse or improve frailty such as osteoporosis. In patients desiring improved athletic performance, an increase in overall strength may also provide as such. There may be an increase in red blood cell production or effectiveness, and an increase in oxygenated blood. As such, mental as well as physical performance may be improved.

20 [0015] The OB protein may be selected from recombinant murine set forth below (SEQ. ID No. 2), or recombinant human protein as set forth in Zhang et al., *Nature, supra*, herein incorporated by reference) or those lacking a glutaminyly residue at position 28. (See Zhang et al., *Nature, supra*, at page 428.) One may also use the recombinant human OB protein analog as set forth in SEQ.ID.NO. 4, which contains 1) an arginine in place of lysine at position 35 and 2) a leucine in place of isoleucine at position 74. (A shorthand abbreviation for this analog is the recombinant human R->K<sup>35</sup>, L->I<sup>74</sup>). The amino acid sequences for the recombinant human analog and recombinant murine proteins are set forth below with a methionyl residue at the -1 position, however, as with any of the present OB proteins and analogs, the methionyl residue may be absent.

25 [0016] The murine protein is substantially homologous to the human protein, particularly as a mature protein, and, further, particularly at the N-terminus. One may prepare an analog of the recombinant human protein by altering (such as substituting amino acid residues), in the recombinant human sequence, the amino acids which diverge from the murine sequence. Because the recombinant human protein has biological activity in mice, such analog would likely be active in humans. For example, using a human protein having a lysine at residue 35 and an isoleucine at residue 74 according to the numbering of SEQ. ID NO. 4, wherein the first amino acid is valine, and the amino acid at position 146 is cysteine, one may substitute with another amino acid one or more of the amino acids at positions 32, 35, 50, 64, 68, 71, 74, 77, 89, 97, 100, 105, 106, 107, 108, 111, 118, 136, 138, 142, and 145. One may select the amino acid at the corresponding position of the murine protein, (SEQ. ID. NO. 2), or another amino acid.

30 [0017] One may further prepare "consensus" molecules based on the rat OB protein sequence. Murakami et al., *Biochem.Biophys. Res. Comm.* **209**: 944-952 (1995) herein incorporated by reference. Rat OB protein differs from human OB protein at the following positions (using the numbering of SEQ. ID. NO. 4): **4, 32, 33, 35, 50, 68, 71, 74, 77, 78, 89, 97, 100, 101, 102, 105, 106, 107, 108, 111, 118, 136, 138** and **145**. One may substitute with another amino acid one or more of the amino acids at these divergent positions. The positions in bold print are those which in which the murine OB protein as well as the rat OB protein are divergent from the human OB protein, and thus, are particularly suitable for alteration. At one or more of these positions, one may substitute an amino acid from the corresponding rat OB protein, or another amino acid.

35 [0018] The positions from both rat and murine OB protein which diverge from the mature human OB protein are: 4, 32, 33, 35, 50, 64, 68, 71, 74, 77, 78, 89, 97, 100, 102, 105, 106, 107, 108, 111, 118, 136, 138, 142, and 145. A human OB protein according to SEQ. ID. NO. 4 (with lysine at position 35 and isoleucine at position 74) having one or more of the above amino acids deleted or replaced with another amino acid, such as the amino acid found in the corresponding rat or murine sequence, may also be effective.

40 [0019] In addition, the amino acids found in rhesus monkey OB protein which diverge from the mature human OB protein are (with identitites noted in parentheses in one letter amino acid abbreviation): 8 (S), 35 (R), 48(V), 53(Q), 60(I), 66(I), 67(N), 68((L), 89(L), 100(L), 108(E), 112 (D), and 118 (L). Since (as described in Example 2, below) the recombinant human OB protein is active in cynomolgus monkeys, a human OB protein according to SEQ. ID. NO. 4 (with lysine at position 35 and isoleucine at position 74) having one or more of the rhesus monkey divergent amino acids replaced with another amino acid, such as the amino acids in parentheses, may be effective. It should be noted that certain rhesus divergent amino acids are also those found in the above murine species (positions 35, 68, 89, 100 and 112). Thus, one may prepare a murine/rhesus/human consensus molecule having (using the numbering of SEQ.ID.

NO. 4 having a lysine at position 35 and an isoleucine at position 74) having one or more of the amino acids at positions replaced by another amino acid: 4, 8, 32, 33, 35, 48, 50, 53, 60, 64, 66, 67, 68, 71, 74, 77, 78, 89, 97, 100, 102, 105, 106, 107, 108, 111, 112, 118, 136, 138, 142, and 145.

[0020] Other analogs may be prepared by deleting a part of the protein amino acid sequence. For example, the mature protein lacks a leader sequence (-22 to -1). One may prepare the following truncated forms of human OB protein molecules (using the numbering of SEQ. ID. NO. 4) :

- (a) amino acids 98-146
- (b) amino acids 1-32
- (c) amino acids 40-116
- (d) amino acids 1-99 and (connected to) 112-146
- (e) amino acids 1-99 and (connected to) 112-146 having one or more of amino acids 100-111 placed between amino acids 99 and 112.

[0021] In addition, the truncated forms may also have altered one or more of the amino acids which are divergent (in the rhesus, rat or murine OB protein) from human OB protein. Furthermore, any alterations may be in the form of altered amino acids, such as peptidomimetics or D-amino acids.

[0022] The present protein (herein the term "protein" is used to include "peptide" and OB analogs, such as those recited *infra*, unless otherwise indicated) may also be derivatized by the attachment of one or more chemical moieties to the protein moiety. The chemically modified derivatives may be further formulated for intraarterial, intraperitoneal, intramuscular, subcutaneous, intravenous, oral, nasal, pulmonary, topical or other routes of administration. Chemical modification of biologically active proteins has been found to provide additional advantages under certain circumstances, such as increasing the stability and circulation time of the therapeutic protein and decreasing immunogenicity. See U.S. Patent No. 4,179,337, Davis et al., issued December 18, 1979. For a review, see Abuchowski et al., in Enzymes as Drugs. (J.S. Holcerberg and J. Roberts, eds. pp. 367-383 (1981)). A review article describing protein modification and fusion proteins is Francis, Focus on Growth Factors 3: 4-10 (May 1992) (published by Mediscript, Mountview Court, Friern Barnet Lane, London N20, OLD, UK).

[0023] The chemical moieties suitable for derivatization may be selected from among various water soluble polymers. The polymer selected should be water soluble so that the protein to which it is attached does not precipitate in an aqueous environment, such as a physiological environment. Preferably, for therapeutic use of the end-product preparation, the polymer will be pharmaceutically acceptable. One skilled in the art will be able to select the desired polymer based on such considerations as whether the polymer/protein conjugate will be used therapeutically, and if so, the desired dosage, circulation time, resistance to proteolysis, and other considerations. For the present proteins and peptides, the effectiveness of the derivatization may be ascertained by administering the derivative, in the desired form (i.e., by osmotic pump, or, more preferably, by injection or infusion, or, further formulated for oral, pulmonary or nasal delivery, for example), and observing biological effects as described herein.

[0024] The water soluble polymer may be selected from the group consisting of, for example, polyethylene glycol, copolymers of ethylene glycol/propylene glycol, carboxymethylcellulose, dextran, polyvinyl alcohol, polyvinyl pyrrolidone, poly-1, 3-dioxolane, poly-1,3,6-trioxane, ethylene/maleic anhydride copolymer, polyaminoacids (either homopolymers or random or non-random copolymers), and dextran or poly(n-vinyl pyrrolidone)polyethylene glycol, propylene glycol homopolymers, polypropylene oxide/ethylene oxide co-polymers, polyoxyethylated polyols, polystyrenemaleate and polyvinyl alcohol. Polyethylene glycol propionaldehyde may have advantages in manufacturing due to its stability in water.

[0025] Fusion proteins may be prepared by attaching polyaminoacids to the OB protein (or analog) moiety. For example, the polyamino acid may be a carrier protein which serves to increase the circulation half life of the protein. For the present therapeutic or cosmetic purposes, such polyamino acid should be those which have do not create neutralizing antigenic response, or other adverse response. Such polyamino acid may be selected from the group consisting of serum album (such as human serum albumin), an antibody or portion thereof (such as an antibody constant region, sometimes called "F<sub>c</sub>") or other polyamino acids. As indicated below, the location of attachment of the polyamino acid may be at the N-terminus of the OB protein moiety, or other place, and also may be connected by a chemical "linker" moiety to the OB protein.

[0026] The polymer may be of any molecular weight, and may be branched or unbranched. For polyethylene glycol, the preferred molecular weight is between about 2 kDa and about 100 kDa (the term "about" indicating that in preparations of polyethylene glycol, some molecules will weigh more, some less, than the stated molecular weight) for ease in handling and manufacturing. Other sizes may be used, depending on the desired therapeutic profile (e.g., the duration of sustained release desired, the effects, if any on biological activity, the ease in handling, the degree or lack of antigenicity and other known effects of the polyethylene glycol to a therapeutic protein or analog).

[0027] The number of polymer molecules so attached may vary, and one skilled in the art will be able to ascertain the

effect on function. One may mono-derivatize, or may provide for a di-, tri-, tetra- or some combination of derivatization, with the same or different chemical moieties (e.g., polymers, such as different weights of polyethylene glycols). The proportion of polymer molecules to protein (or peptide) molecules will vary, as will their concentrations in the reaction mixture. In general, the optimum ratio (in terms of efficiency of reaction in that there is no excess unreacted protein or polymer) will be determined by factors such as the desired degree of derivatization (e.g., mono, di-, tri-, etc.), the molecular weight of the polymer selected, whether the polymer is branched or unbranched, and the reaction conditions.

[0028] The chemical moieties should be attached to the protein with consideration of effects on functional or antigenic domains of the protein. There are a number of attachment methods available to those skilled in the art. E.g., EP 0 401 384 herein incorporated by reference (coupling PEG to G-CSF), see also Malik et al., Exp. Hematol. 20: 1028-1035

(1992) (reporting pegylation of GM-CSF using tresyl chloride). For example, polyethylene glycol may be covalently bound through amino acid residues via a reactive group, such as, a free amino or carboxyl group. Reactive groups are those to which an activated polyethylene glycol molecule may be bound. The amino acid residues having a free amino group may include lysine residues and the N-terminal amino acid residue. Those having a free carboxyl group may include aspartic acid residues, glutamic acid residues, and the C-terminal amino acid residue. Sulfhydryl groups may also be used as a reactive group for attaching the polyethylene glycol molecule(s). Preferred for therapeutic purposes is attachment at an amino group, such as attachment at the N-terminus or lysine group. Attachment at residues important for receptor binding should be avoided if receptor binding is desired.

[0029] One may specifically desire N-terminally chemically modified protein. Using polyethylene glycol as an illustration of the present compositions, one may select from a variety of polyethylene glycol molecules (by molecular weight, branching, etc.), the proportion of polyethylene glycol molecules to protein molecules in the reaction mix, the type of pegylation reaction to be performed, and the method of obtaining the selected N-terminally pegylated protein. The method of obtaining the N-terminally pegylated preparation (i.e., separating this moiety from other monopegylated moieties if necessary) may be by purification of the N-terminally pegylated material from a population of pegylated protein molecules. Selective N-terminal chemical modification may be accomplished by reductive alkylation which exploits differential reactivity of different types of primary amino groups (lysine versus the N-terminal) available for derivatization in a particular protein. Under the appropriate reaction conditions, substantially selective derivatization of the protein at the N-terminus with a carbonyl group containing polymer is achieved. For example, one may selectively N-terminally pegylate the protein by performing the reaction at a pH which allows one to take advantage of the  $\text{pK}_a$  differences between the  $\epsilon$ -amino group of the lysine residues and that of the  $\alpha$ -amino group of the N-terminal residue of the protein.

By such selective derivatization, attachment of a water soluble polymer to a protein is controlled: the conjugation with the polymer takes place predominantly at the N-terminus of the protein and no significant modification of other reactive groups, such as the lysine side chain amino groups, occurs. Using reductive alkylation, the water soluble polymer may be of the type described above, and should have a single reactive aldehyde for coupling to the protein. Polyethylene glycol propionaldehyde, containing a single reactive aldehyde, may be used.

[0030] An N-terminally monopegylated derivative is preferred for ease in production of a therapeutic. N-terminal pegylation ensures a homogenous product as characterization of the product is simplified relative to di-, tri- or other multi pegylated products. The use of the above reductive alkylation process for preparation of an N-terminal product is preferred for ease in commercial manufacturing.

[0031] In yet another aspect of the present invention, provided are methods of using pharmaceutical compositions of the proteins, and derivatives. Such pharmaceutical compositions may be for administration by injection, or for oral, pulmonary, nasal, transdermal or other forms of administration. In general, comprehended by the invention are pharmaceutical compositions comprising effective amounts of protein or derivative products of the invention together with pharmaceutically acceptable diluents, preservatives, solubilizers, emulsifiers, adjuvants and/or carriers. Such compositions include diluents of various buffer content (e.g., Tris-HCl, acetate, phosphate), pH and ionic strength; additives such as detergents and solubilizing agents (e.g., Tween 80, Polysorbate 80), anti-oxidants (e.g., ascorbic acid, sodium metabisulfite), preservatives (e.g., Thimersol, benzyl alcohol) and bulking substances (e.g., lactose, mannitol); incorporation of the material into particulate preparations of polymeric compounds such as polylactic acid, polyglycolic acid, etc. or into liposomes. Hylauronic acid may also be used, and this may have the effect of promoting sustained duration in the circulation. Such compositions may influence the physical state, stability, rate of *in vivo* release, and rate of *in vivo* clearance of the present proteins and derivatives. See, e.g., Remington's Pharmaceutical Sciences, 18th Ed. (1990, Mack Publishing Co., Easton, PA 18042) pages 1435-1712 which are herein incorporated by reference. The compositions may be prepared in liquid form, or may be in dried powder, such as lyophilized form. Implantable sustained release formulations are also contemplated, as are transdermal formulations.

[0032] Contemplated for use herein are oral solid dosage forms, which are described generally in Remington's Pharmaceutical Sciences, 18th Ed. 1990 (Mack Publishing Co. Easton PA 18042) at Chapter 89, which is herein incorporated by reference. Solid dosage forms include tablets, capsules, pills, troches or lozenges, cachets or pellets. Also, liposomal or proteinoid encapsulation may be used to formulate the present compositions (as, for example, proteinoid microspheres reported in U.S. Patent No. 4,925,673). Liposomal encapsulation may be used and the liposomes may

be derivatized with various polymers (E.g., U.S. Patent No. 5,013,556). A description of possible solid dosage forms for the therapeutic is given by Marshall, K. In: *Modern Pharmaceutics* Edited by G.S. Banker and C.T. Rhodes Chapter 10, 1979, herein incorporated by reference. In general, the formulation will include the protein (or analog or derivative), and inert ingredients which allow for protection against the stomach environment, and release of the biologically active material in the intestine.

[0033] Also specifically contemplated are oral dosage forms of the above derivatized proteins. Protein may be chemically modified so that oral delivery of the derivative is efficacious. Generally, the chemical modification contemplated is the attachment of at least one moiety to the protein (or peptide) molecule itself, where said moiety permits (a) inhibition of proteolysis; and (b) uptake into the blood stream from the stomach or intestine. Also desired is the increase in overall stability of the protein and increase in circulation time in the body. Examples of such moieties include: Polyethylene glycol, copolymers of ethylene glycol and propylene glycol, carboxymethyl cellulose, dextran, polyvinyl alcohol, polyvinyl pyrrolidone and polyproline. Abuchowski and Davis, *Soluble Polymer-Enzyme Adducts*. In: "Enzymes as Drugs", Hocenberg and Roberts, eds., Wiley-Interscience, New York, NY, (1981), pp 367-383; Newmark, et al., *J. Appl. Biochem.* 4: 185-189 (1982). Other polymers that could be used are poly-1,3-dioxolane and poly-1,3,6-tioxocane.

[0034] For the protein (or derivative) the location of release may be the stomach, the small intestine (the duodenum, the jejunum, or the ileum), or the large intestine. One skilled in the art has available formulations which will not dissolve in the stomach, yet will release the material in the duodenum or elsewhere in the intestine. Preferably, the release will avoid the deleterious effects of the stomach environment, either by protection of the protein (or derivative) or by release of the biologically active material beyond the stomach environment, such as in the intestine.

[0035] To ensure full gastric resistance a coating impermeable to at least pH 5.0 is essential. Examples of the more common inert ingredients that are used as enteric coatings are cellulose acetate trimellitate (CAT), hydroxypropylmethylcellulose phthalate (HPMCP), HPMCP 50, HPMCP 55, polyvinyl acetate phthalate (PVAP), Eudragit L30D. Aquateric, cellulose acetate phthalate (CAP), Eudragit L, Eudragit S, and Shellac. These coatings may be used as mixed films.

[0036] A coating or mixture of coatings can also be used on tablets, which are not intended for protection against the stomach. This can include sugar coatings, or coatings which make the tablet easier to swallow. Capsules may consist of a hard shell (such as gelatin) for delivery of dry therapeutic i.e. powder; for liquid forms, a soft gelatin shell may be used. The shell material of cachets could be thick starch or other edible paper. For pills, lozenges, molded tablets or tablet triturates, moist massing techniques can be used.

[0037] The therapeutic can be included in the formulation as fine multiparticulates in the form of granules or pellets of particle size about 1mm. The formulation of the material for capsule administration could also be as a powder, lightly compressed plugs or even as tablets. The therapeutic could be prepared by compression.

[0038] Colorants and flavoring agents may all be included. For example, the protein (or derivative) may be formulated (such as by liposome or microsphere encapsulation) and then further contained within an edible product, such as a refrigerated beverage containing colorants and flavoring agents.

[0039] One may dilute or increase the volume of the therapeutic with an inert material. These diluents could include carbohydrates, especially mannitol,  $\alpha$ -lactose, anhydrous lactose, cellulose, sucrose, modified dextrans and starch. Certain inorganic salts may be also be used as fillers including calcium triposphate, magnesium carbonate and sodium chloride. Some commercially available diluents are Fast-Flo, Emdex, STA-Rx 1500, Emcompress and Avicell.

[0040] Disintegrants may be included in the formulation of the therapeutic into a solid dosage form. Materials used as disintegrates include but are not limited to starch including the commercial disintegrant based on starch, Explotab. Sodium starch glycolate, Amberlite, sodium carboxymethylcellulose, ultramylopectin, sodium alginate, gelatin, orange peel, acid carboxymethyl cellulose, natural sponge and bentonite may all be used. Another form of the disintegrants are the insoluble cationic exchange resins. Powdered gums may be used as disintegrants and as binders and these can include powdered gums such as agar, Karaya or tragacanth. Alginic acid and its sodium salt are also useful as disintegrants.

[0041] Binders may be used to hold the therapeutic agent together to form a hard tablet and include materials from natural products such as acacia, tragacanth, starch and gelatin. Others include methyl cellulose (MC), ethyl cellulose (EC) and carboxymethyl cellulose (CMC). Polyvinyl pyrrolidone (PVP) and hydroxypropylmethyl cellulose (HPMC) could both be used in alcoholic solutions to granulate the therapeutic.

[0042] An antifrictional agent may be included in the formulation of the therapeutic to prevent sticking during the formulation process. Lubricants may be used as a layer between the therapeutic and the die wall, and these can include but are not limited to; stearic acid including its magnesium and calcium salts, polytetrafluoroethylene (PTFE), liquid paraffin, vegetable oils and waxes. Soluble lubricants may also be used such as sodium lauryl sulfate, magnesium lauryl sulfate, polyethylene glycol of various molecular weights, Carbowax 4000 and 6000.

[0043] Glidants that might improve the flow properties of the drug during formulation and to aid rearrangement during compression might be added. The glidants may include starch, talc, pyrogenic silica and hydrated silicoaluminate.

[0044] To aid dissolution of the therapeutic into the aqueous environment a surfactant might be added as a wetting agent. Surfactants may include anionic detergents such as sodium lauryl sulfate, dioctyl sodium sulfosuccinate and

5 dioctyl sodium sulfonate. Cationic detergents might be used and could include benzalkonium chloride or benzethonium chloride. The list of potential nonionic detergents that could be included in the formulation as surfactants are lauromacrogol 400, polyoxy 40 stearate, polyoxyethylene hydrogenated castor oil 10, 50 and 60, glycerol monostearate, polysorbate 40, 60, 65 and 80, sucrose fatty acid ester, methyl cellulose and carboxymethyl cellulose. These surfactants could be present in the formulation of the protein or derivative either alone or as a mixture in different ratios.

10 [0045] Additives which potentially enhance uptake of the protein (or derivative) are for instance the fatty acids oleic acid, linoleic acid and linolenic acid.

15 [0046] Controlled release formulation may be desirable. The drug could be incorporated into an inert matrix which permits release by either diffusion or leaching mechanisms i.e. gums. Slowly degenerating matrices may also be incorporated into the formulation. Another form of a controlled release of this therapeutic is by a method based on the Oros therapeutic system (Alza Corp.), i.e. the drug is enclosed in a semipermeable membrane which allows water to enter and push drug out through a single small opening due to osmotic effects. Some enteric coatings also have a delayed release effect.

20 [0047] Other coatings may be used for the formulation. These include a variety of sugars which could be applied in a coating pan. The therapeutic agent could also be given in a film coated tablet and the materials used in this instance are divided into 2 groups. The first are the nonenteric materials and include methyl cellulose, ethyl cellulose, hydroxyethyl cellulose, methylhydroxy-ethyl cellulose, hydroxypropyl cellulose, hydroxypropyl-methyl cellulose, sodium carboxymethyl cellulose, providone and the polyethylene glycols. The second group consists of the enteric materials that are commonly esters of phthalic acid.

25 [0048] A mix of materials might be used to provide the optimum film coating. Film coating may be carried out in a pan coater or in a fluidized bed or by compression coating.

30 [0049] Also contemplated herein is pulmonary delivery of the present protein, or derivative thereof. The protein (derivative) is delivered to the lungs of a mammal while inhaling and traverses across the lung epithelial lining to the blood stream. (Other reports of this include Adjei et al., *Pharmaceutical Research* **7**: 565-569 (1990); Adjei et al., *International Journal of Pharmaceutics* **63**: 135-144 (1990) (leuprolide acetate); Braquet et al., *Journal of Cardiovascular Pharmacology* **13**(suppl. 5): s.143-146 (1989) (endothelin-1); Hubbard et al., *Annals of Internal Medicine* **3**: 206-212 (1989) ( $\alpha$ 1-antitrypsin); Smith et al., *J. Chin. Invest.* **84**: 1145-1146 (1989) ( $\alpha$ -1-proteinase); Oswein et al., "Aerosolization of Proteins", *Proceedings of Symposium on Respiratory Drug Delivery II*, Keystone, Colorado, March, 1990 (recombinant human growth hormone); Debs et al., *The Journal of Immunology* **140**: 3482-3488 (1988) (interferon- $\gamma$  and tumor necrosis factor alpha) and Platz et al., U.S. Patent No. 5,284,656 (granulocyte colony stimulating factor)

35 [0050] Contemplated for use in the practice of this invention are a wide range of mechanical devices designed for pulmonary delivery of therapeutic products, including but not limited to nebulizers, metered dose inhalers, and powder inhalers, all of which are familiar to those skilled in the art.

40 [0051] Some specific examples of commercially available devices suitable for the practice of this invention are the Ultravent nebulizer, manufactured by Mallinckrodt, Inc., St. Louis, Missouri; the Acorn II nebulizer, manufactured by Marquest Medical Products, Englewood, Colorado; the Ventolin metered dose inhaler, manufactured by Glaxo Inc., Research Triangle Park, North Carolina; and the Spinhaler powder inhaler, manufactured by Fisons Corp., Bedford, Massachusetts.

45 [0052] All such devices require the use of formulations suitable for the dispensing of protein (or analog or derivative). Typically, each formulation is specific to the type of device employed and may involve the use of an appropriate propellant material, in addition to diluents, adjuvants and/or carriers useful in therapy.

50 [0053] The protein (or derivative) should most advantageously be prepared in particulate form with an average particle size of less than 10  $\mu\text{m}$  (or microns), most preferably 0.5 to 5  $\mu\text{m}$ , for most effective delivery to the distal lung.

55 [0054] Carriers include carbohydrates such as trehalose, mannitol, xylitol, sucrose, lactose, and sorbitol. Other ingredients for use in formulations may include DPPC, DOPE, DSPC and DOPC. Natural or synthetic surfactants may be used. Polyethylene glycol may be used (even apart from its use in derivatizing the protein or analog). Dextrans, such as cyclodextran, may be used. Bile salts and other related enhancers may be used. Cellulose and cellulose derivatives may be used. Amino acids may be used, such as use in a buffer formulation.

60 [0055] Also, the use of liposomes, microcapsules or microspheres, inclusion complexes, or other types of carriers is contemplated.

65 [0056] Formulations suitable for use with a nebulizer, either jet or ultrasonic, will typically comprise protein (or derivative) dissolved in water at a concentration of about 0.1 to 25 mg of biologically active protein per mL of solution. The formulation may also include a buffer and a simple sugar (e.g., for protein stabilization and regulation of osmotic pressure). The nebulizer formulation may also contain a surfactant, to reduce or prevent surface induced aggregation of the protein caused by atomization of the solution in forming the aerosol.

70 [0057] Formulations for use with a metered-dose inhaler device will generally comprise a finely divided powder containing the protein (or derivative) suspended in a propellant with the aid of a surfactant. The propellant may be any conventional material employed for this purpose, such as a chlorofluorocarbon, a hydrochlorofluorocarbon, a

hydrofluorocarbon, or a hydrocarbon, including trichlorofluoromethane, dichlorodifluoromethane, dichlorotetrafluoroethanol, and 1,1,1,2-tetrafluoroethane, or combinations thereof. Suitable surfactants include sorbitan trioleate and soya lecithin. Oleic acid may also be useful as a surfactant.

[0058] Formulations for dispensing from a powder inhaler device will comprise a finely divided dry powder containing protein (or derivative) and may also include a bulking agent, such as lactose, sorbitol, sucrose, mannitol, trehalose, or xylitol in amounts which facilitate dispersal of the powder from the device, e.g., 50 to 90% by weight of the formulation.

[0059] Nasal delivery of the protein (or analog or derivative) is also contemplated. Nasal delivery allows the passage of the protein to the blood stream directly after administering the therapeutic product to the nose, without the necessity for deposition of the product in the lung. Formulations for nasal delivery include those with dextran or cyclodextran.

10 Delivery via transport across other mucus membranes is also contemplated.

[0060] One skilled in the art will be able to ascertain effective dosages by administration and observing the desired therapeutic effect. Preferably, the formulation of the molecule will be such that between about .10 µg/kg/day and 10 mg/kg/day will yield the desired therapeutic effect. The effective dosages may be determined using diagnostic tools over time. For example, a diagnostic for measuring the amount of OB protein in the blood (or plasma or serum) may first be used to determine endogenous levels of OB protein. Such diagnostic tool may be in the form of an antibody assay, such as an antibody sandwich assay. The amount of endogenous OB protein is quantified initially, and a baseline is determined. The therapeutic dosages are determined as the quantification of endogenous and exogenous OB protein (that is, protein, analog or derivative found within the body, either self-produced or administered) is continued over the course of therapy. The dosages may therefore vary over the course of therapy, with a relatively high dosage being used initially,

20 until therapeutic benefit is seen, and lower dosages used to maintain the therapeutic benefits.

[0061] Ideally, in situations where solely an increase in lean body mass is desired, the dosage will be insufficient to result in weight loss. Thus, during an initial course of therapy of an obese person, dosages may be administered whereby weight loss and concomitant fat tissue decrease/lean mass increase is achieved. Once sufficient weight loss is achieved, a dosage sufficient to prevent re-gaining weight, yet sufficient to maintain desired lean mass increase (or, prevention of lean mass depletion) may be administered. These dosages can be determined empirically, as the effects of OB protein are reversible. E.g., Campfield et al., Science 269: 546-549 (1995) at 547. Thus, if a dosage resulting in weight loss is observed when weight loss is not desired, one would administer a lower dose in order to achieve the desired increase in lean tissue mass, yet maintain the desired weight.

[0062] For increasing an individual's sensitivity to insulin, similar dosage considerations may be taken into account. Lean mass increase without weight loss may be achieved sufficient to decrease the amount of insulin (or, potentially, amylin or other potential diabetes treating drugs) an individual would be administered for the treatment of diabetes.

[0063] For increasing overall strength, there may be similar dosage considerations. Lean mass increase with concomitant increase in overall strength may be achieved with doses insufficient to result in weight loss. Other benefits, such as an increase in red blood cells (and oxygenation in the blood) and a decrease in bone resorption or osteoporosis may also be achieved in the absence of weight loss.

[0064] The present methods may be used in conjunction with other medicaments, such as those useful for the treatment of diabetes (e.g., insulin, and possibly amylin), cholesterol and blood pressure lowering medicaments (such as those which reduce blood lipid levels or other cardiovascular medicaments), and activity increasing medicaments (e.g., amphetamines). Appetite suppressants may also be used. Such administration may be simultaneous or may be in seriatim.

[0065] In addition, the present methods may be used in conjunction with surgical procedures, such as cosmetic surgeries designed to alter the overall appearance of a body (e.g., liposuction or laser surgeries designed to reduce body mass, or implant surgeries designed to increase the appearance of body mass). The health benefits of cardiac surgeries, such as bypass surgeries or other surgeries designed to relieve a deleterious condition caused by blockage of blood vessels by fatty deposits, such as arterial plaque, may be increased with concomitant use of the present compositions and methods. Methods to eliminate gall stones, such as ultrasonic or laser methods, may also be used either prior to, during or after a course of the present therapeutic methods. Furthermore, the present methods may be used as an adjunct to surgeries or therapies for broken bones, damaged muscle, or other therapies which would be improved by an increase in lean tissue mass.

[0066] Therefore, the present invention provides a method for increasing lean tissue mass, comprised of administering an effective amount of an OB protein, analog or derivative thereof selected from among:

- (a) the amino acid sequence 1-146 as set forth in SEQ. ID. NO. 2 (below) or SEQ ID. NO. 4 (below),
- (b) the amino acid sequence set 1-146 as forth in SEQ. ID. NO. 4 (below) having a lysine residue at position 35 and an isoleucine residue at position 74;
- (c) the amino acid sequence of subpart (b) having a different amino acid substituted in one or more of the following positions (using the numbering according to SEQ. ID. NO. 4, and retaining the same numbering even in the absence of a glutaminyl residue at position 28) : 4, 8, 32, 33, 35, 48, 50, 53, 60, 64, 66, 67, 68, 71, 74, 77, 78, 89,

97, 100, 102, 105, 106, 107, 108, 111, 112, 118, 136, 138, 142, and 145;

(d) the amino acid sequence of subparts (a), (b) or (c) optionally lacking a glutaminyl residue at position 28;

(e) the amino acid sequence of subparts (a), (b), (c), or (d) having a methionyl residue at the N terminus.

(f) a truncated OB protein analog selected from among: (using the numbering of SEQ. ID. NO. 4 having a lysine residue at position 35 and an isoleucine residue at position 74) :

(i) amino acids 98-146

(ii) amino acids 1-32

(iii) amino acids 40-116

(iv) amino acids 1-99 and 112-146

(v) amino acids 1-99 and 112-146 having one or more of amino acids 100-111 sequentially placed between amino acids 99 and 112; and,

(vi) the truncated OB analog of subpart (i) having one or more of amino acids 100, 102, 105, 106, 107, 108, 111, 112, 118, 136, 138, 142, and 145 substituted with another amino acid;

(vii) the truncated analog of subpart (ii) having one or more of amino acids 4, 8 and 32 substituted with another amino acid;

(viii) the truncated analog of subpart (iii) having one or more of amino acids 50, 53, 60, 64, 66, 67, 68, 71, 74, 77, 78, 89, 97, 100, 102, 105, 106, 107, 108, 111 and 112 replaced with another amino acid;

(ix) the truncated analog of subpart (iv) having one or more of amino acids 4, 8, 32, 33, 35, 48, 50, 53, 60, 64, 66, 67, 68, 71, 74, 77, 78, 89, 97, 112, 118, 136, 138, 142, and 145 replaced with another amino acid;

(x) the truncated analog of subpart (v) having one or more of amino acids 4, 8, 32, 33, 35, 48, 50, 53, 60, 64, 66, 67, 68, 71, 74, 77, 78, 89, 97, 100, 102, 105, 106, 107, 108, 111, 112, 118, 136, 138, 142, and 145 replaced with another amino acid;

(xi) the truncated analog of any of subparts (i)-(x) having an N-terminal methionyl residue; and

(g) the OB protein or analog derivative of any of subparts (a) through (f) comprised of a chemical moiety connected to the protein moiety;

(h) a derivative of subpart (g) wherein said chemical moiety is a water soluble polymer moiety;

(i) a derivative of subpart (h) wherein said water soluble polymer moiety is polyethylene glycol;

(j) A derivative of subpart (h) wherein said water soluble polymer moiety is a polyamino acid moiety;

(k) a derivative of subpart (h) wherein said water soluble polymer moiety is attached at solely the N-terminus of said protein moiety

(l) an OB protein, analog or derivative of any of subparts (a) through (k) in a pharmaceutically acceptable carrier.

[0067] The following examples are offered to more fully illustrate the invention, but are not to be construed as limiting the scope thereof. Example 1 demonstrates that OB protein is effective for increasing lean mass in non-obese animals. Example 2 demonstrates that OB protein is effective for increasing lean mass in obese primates. Example 3 through 5 are prophetic examples of human use. Materials and Methods follow.

#### EXAMPLE 1

[0068] These data demonstrate that the OB protein, or analogs or derivatives thereof, is effective for increasing lean mass.

[0069] Recombinant methionyl murine OB protein (as described below) was continuously administered via osmotic pump infusion for a period of four weeks. Table 1 data show the average body composition (for CD1 mice) at the doses indicated:

TABLE 1

Dose (mg/kg/day)	Water (g)	Fat (g)	Lean Mass (g)
PBS	22.13 +/- .33	8.39 +/- .67	3.2 +/- .28
0.03	22.09 +/- .55	9.44 +/- .61	2.32 +/- .54
0.1	21.02 +/- .44	6.64 +/- .1	3.85 +/- .57
0.3	22.02 +/- .31	5.22 +/- .91	4.72 +/- .48
1.0	21.34 +/- .38	1.51 +/- .48	6.94 +/- .25

In non-obese CD1 mice, recombinant methionyl murine OB protein continuously administered at a doses of either 0.3 or 1 mg/kg/day was shown to effect an increase in lean mass relative to the control animals, who were administered PBS.

5    EXAMPLE 2

[0070] This Example demonstrates that recombinant methionyl human OB protein causes lean tissue mass increase in primates.

[0071] 10    Obese cynomolgus monkeys having greater than 20% body fat were administered recombinant methionyl human OB protein subcutaneously, at a daily dose of 1 mg protein/kg body weight/day (see Materials and Methods, below). Control animals were administered phosphate buffered saline. Body composition was performed using Dual Energy X-Ray Absorptiometry ("DEXA") analysis. Measurements of body composition were taken at 7 day intervals.

[0072] 15    Tables 2A and 2B show the results of body composition analysis in terms of mass of fat or lean tissue. Data are presented in grams. Results for the 2 control animals are in Table 2A. The data for 4 test animals are presented in Table 2B. (Data for bone mass are also presented). As can be seen, at day 28, the test animals lost approximately 264 grams of fat, and gained approximately 138 grams of lean mass. At day 28, the controls lost 36 grams of fat tissue and gained approximately 25 grams of lean mass. This demonstrates that OB protein causes an increase in lean tissue mass.

20

TABLE 2A

CONTROL (n=2)	BASELINE	DAY 7	DAY 14	DAY 21	DAY 28
LEAN MASS ± STD DEV	5393 ±894	5411 ±863	5467 ±934	5410 ±983	5418 ±802
FAT MASS ± STD DEV	2884 ±1962	2838 ±1936	2835 ±2113	2852 ±2271	2848 ±2122
BONE MASS ± STD DEV	325 ±12	324 ±4	324 ±11	325 ±16	321 ±7

25

30

35

TABLE 2B

OB PROTEIN (n=4)	BASELINE	DAY 7	DAY 14	DAY 21	DAY 28
LEAN MASS ± STD DEV	4877 ±960	4782 ±927	4899 ±1037	4957 ±1053	5015 * ±1192
FAT MASS ± STD DEV	2577 ±1927	2536 ±1982	2432 ±1874	2380 ±1924	2313 * ±1903
BONE MASS ± STD DEV	296 ±96	296 ±99	294 ±97	292 ±96	291 ±96

\* indicates p-value less than 0.05 for repeated measures ANOVA

40

45

50

EXAMPLE 3

[0073] 55    A non-obese human patient desires an increase in lean tissue mass for therapeutic purposes, such, as recovery from illness which depleted lean tissue mass. The patient is administered an effective amount of OB protein, analog or derivative thereof to result in the desired increase in lean tissue mass. Increase in lean tissue mass is monitored using DEXA Scanning. Levels of circulating OB protein or analog or derivative may be monitored using a diagnostic kit, such as an antibody assay against the OB protein (or other antigenic source if applicable).

EXAMPLE 4

[0074] A human subject desires an increase in lean tissue mass for cosmetic or athletic purposes, such as an increase in lean tissue in order to improve outward appearance. The patient is administered an effective amount of OB protein, analog or derivative thereof to result in the desired increase in lean tissue mass. Increase in lean tissue mass is monitored using DEXA scanning. Oxygen levels in the blood increase. Levels of circulating OB protein or analog or derivative may be monitored using a diagnostic kit, such as an antibody assay against the OB protein (or other antigenic source if applicable).

EXAMPLE 5

[0075] A diabetic human patient desires to use decreased dosages of insulin for treatment of diabetes. The patient is administered an effective amount of OB protein, analog or derivative thereof to result in an increase in lean tissue mass. The patient's sensitivity to insulin increases, and the dosage of insulin necessary to alleviate symptoms of diabetes is decreased, either in terms of a decrease in the units of insulin needed, or in terms of a decrease in the number of injections of insulin needed per day. Levels of circulating OB protein or analog or derivative may be monitored using a diagnostic kit, such as an antibody assay against the OB protein (or other antigenic source if applicable).

EXAMPLE 6

[0076] A non-obese elderly human patient desires an increase in overall strength. The patient is administered an effective amount of OB protein, analog or derivative thereof to result in an increase in lean tissue mass, and increase in overall strength. Bone resorption is also decreased, and an osteoporosis condition is improved. Levels of circulating OB protein or analog or derivative may be monitored using a diagnostic kit, such as an antibody assay against the OB protein (or other antigenic source if applicable).

MATERIALS AND METHODSAnimals:

[0077]

Rodents. Wild type CD1 mice were used for Example 1 (Table 1 data). Animals were maintained under humane conditions.

Primates: A total of six cynomolgus monkeys were used. All monkeys were at least 20% fat at the outset of the study. Animals were randomized for weight, and four animals were tested with OB protein, two animals were controls.

Administration of Protein or Vehicle.

[0078]

For Rodents. For Example 1, (Table 1 data) recombinant murine protein (as described below) or vehicle (phosphate buffered saline, "PBS", pH 7.4) was administered by osmotic pump infusion. Alzet osmotic minipumps (Alza, Palo Alto, CA, model no. 2002) were surgically placed in each mouse in a subcutaneous pocket in the subscapular area, and replaced after two weeks. The pumps were calibrated to administer 0.5  $\mu$  protein in solution per hour for the dosages indicated in Table 1.

For Primates. For Example 2, recombinant methionyl human OB protein (of SEQ.ID. NO.4 having a lysine at position 35 and an isoleucine at position 74), dosed at 1 mg/ml PBS, was administered subcutaneously at a dose of 1 mg protein/kg body weight/day. Control animals were administered PBS in the same fashion.

Rodent Carcass Analysis. Carcass analysis was conducted as in A.I. Leshner, V.A. Litwin, and R.L. Squibb, Brain Res. 9: 281 (1972). Water composition was determined by subtraction of carcass weight before and after a 4 day dehydration period. Fat was extracted from a pre-weighed portion of the ground, dried carcass with ethyl ether and ethyl alcohol, so that percent fat could be calculated from the amount of material remaining after the extraction procedure. Lean mass was defined as the proportion of ground carcass that remained after dehydration and ether

**extraction.**

**Primate Dual Energy X-Ray Absorptiometry Scanning:** "DEXA" scanning was performed at the time points indicated in Table 2 A and B, in Example 2.

**5** Protein: Sequence ID Nos. 1 and 2 set forth murine recombinant OB DNA and protein, and Sequence ID Nos. 3 and 4 set forth an analog recombinant human OB DNA and protein. Murine recombinant protein as in SEQ. ID NO. 2 was used in EXAMPLE 1. Recombinant human OB protein as in SEQ.ID. NO. 4 having a lysine residue at position 35 and an isoleucine residue at position 74 was used in EXAMPLE 2. As indicated above, the below murine and **10** human analog recombinant proteins are illustrative of the OB protein which may be used in the present methods of treatment and manufacture of a medicament. Other OB proteins or analogs or derivatives thereof may be used.

[0079] Herein, the first amino acid of the amino acid sequence for recombinant protein is referred to as +1, and is valine, and the amino acid at position -1 is methionine. The C-terminal amino acid is number 146 (cysteine).

Recombinant murine met OB (double stranded) DNA and amino acid sequence (Seq. ID. Nos. 1 and 2):

5

309 GCTGCA CCTGCTGGCATTCTCCAAATCCTGCCTCCCTGCCCGAGACCTCAGGTCTTCAGAA 368  
 CGACGTGGACGACCGTAAGAGGTTAGGACGAGGGACGGCGCTGGAGTCCAGAAGTCTT  
 L H L L A F S K S C S L P Q T S G L Q K -  
  
 369 ACCGGAATCCCTGGACGGGGTCCTGGAAGCATCCCTGTACAGCACCGAAGTTGTTGCTCT 428  
 TGGCCTTAGGGACCTGCCCCAGGACCTTCGTAGGGACATGTCGTGGCTTCACAACAGAGA  
 P E S L D G V L E A S L Y S T E V V A L -  
  
 429 GTCCCCTGCTGCAGGGTTCCCTTCAGGACATCCTTCAGCAGCTGGACGTTCTCCCGAATG 488  
 CAGGGCAGACGTCCAAGGGAAAGTCCTGTAGGAAGTCGTGACCTGCAAAGAGGCCTTAC  
 S R L Q G S L Q D I L Q Q L D V S P E C -  
  
 15 TTAATGGATCC  
 489 AATTACCTAGG

20

Recombinant human met OB analog (Double Stranded) DNA and amino acid sequence (SEQ. ID. Nos. 3 and 4)

25

1 CATATGGTACCGATCCAGAAAGTTCAAGGACACCCAAACCTTAATTAAAACGATCGTT 60  
 GTATAACCATGGCTAGGTCTTCAGTCCTGTGTGGTTTGGAAATTAAATTGGCTAGCAA  
 M V P I Q K V Q D D T K T L I K T I V -

30

61 ACCCGTATCAACGACATCACTCACACCCAGTCGGTGAGCTCTAACACAGCGTGTACAGGC 120  
 TCCGCATAGTTGCTGTAGTCAGTGTGGTCAGCCACTCGAGATTGTCGACAAATGTCCG  
 T R I N D I S H T Q S V S S K Q R V T G -

35

121 CTGGACTTCATCCGGGTCTGCACCCGATCCTGACCTTGTCCA AAAATGGACCAGACCTG 180  
 GACCTGAAGTAGGGCCCAGACGTGGCTAGGACTGGAACAGGTTTACCTGGCTGGGAC  
 L D F I P G L H P I L T L S K M D Q T L -

40

181 CCTGTATACCAAGCAGATCTAACCTCCATGCCGTCCCGTAACGTTCTTCAGATCTCTAAC 240  
 CGACATATGGCTGTAGAATTGGAGGTACGGCAGGGCAATTCCAAGAAGTCTAGAGAGATTG  
 A V Y Q Q I L T S M P S R N V L Q I S N -

45

241 GACCTCGAGAACCTTCGGGACCTGCCACCTGCTGCCACCTGCTCCATTCCTGCCACCTG 300  
 CTGGAGCTCTTGGAAAGCCCTGGACGACGTGCAAGACCGTAAGAGGTTAGGACGGTGGAC  
 D L E N L R D L L H V L A F S K S C H L -

55

301 CCATGGGCTTCAGGTCTTGAGACTCTGGACTCTCTGGCGGGTCTGGAAAGCATCCGT  
 GGTACCCGAAGTCCAGAACCTCTGAGACCTGAGAGACCCGCCAGGACCTCGTAGGCCA  
 P W A S G L E T L D S L G G V L E A S G -  
  
 361 TACACCACCGAAGTTGTTGCTCTGTCGGCTCTGCAGGGTTCCCTTCAGGACATGCTTTGG  
 ATGTCGTGGCTTCACAAACGAGACAGGGCAGACGTCCCAAGGGAGTCCTGTACGAAACC  
 Y S T E V V A L S R L Q G S L Q D M L W -  
  
 421 CAGCTGGACCTGTCTCCGGGTGTTAATGGATCC  
 GTCGACCTGGACAGAGGCCAACATTACCTAGG  
 Q L D L S P G C \*

## METHODS FOR PRODUCTION

[0080] The below methods for production have been used to produce biologically active recombinant methionyl murine or human analog OB protein. Similar methods may be used to prepare biologically active recombinant methionyl human OB protein.

### **30 Expression Vector and Host Strain**

[0081] The plasmid expression vector used is pCFM1656, ATCC Accession No. 69576. The above DNA was ligated into the expression vector pCFM1656 linearized with XbaI and BamHI and transformed into the *E. coli* host strain, FM5. *E. coli* FM5 cells were derived at Amgen Inc., Thousand Oaks, CA from *E. coli* K-12 strain (Bachmann, et al., Bacteriol. Rev. **40**: 116-167 (1976)) and contain the integrated lambda phage repressor gene, cl<sub>857</sub> (Sussman et al., C.R. Acad. Sci. **254**: 1517-1579 (1962)). Vector production, cell transformation, and colony selection were performed by standard methods. E.g., Sambrook, et al., Molecular Cloning: A Laboratory Manual, 2d Edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY. Host cells were grown in LB media.

[0082] **Fermentation Process** A three-phase fermentation protocol known as a fed-batch process was used. Media compositions are set forth below.

Batch: A nitrogen and phosphate source were sterilized (by raising to 122 °C for 35 minutes, 18-20 psi) in the fermentation vessel (Biolafitte, 12 liter capacity). Upon cooling, carbon, magnesium, vitamin, and trace metal sources were added aseptically. An overnight culture of the above recombinant murine protein-producing bacteria (16 hours or more) of 500 mL (grown in LB broth) was added to the fermentor.

**Feed I:** Upon reaching between 4.0-6.0 OD<sub>600</sub>, cultures were fed with Feed I. The glucose was fed at a limiting rate in order to control the growth rate ( $\mu$ ). An automated system (called the Distributive Control System) was instructed to control the growth rate to 0.15 generations per hour.

Feed II: When the OD<sub>600</sub> had reached 30, culture temperature were slowly increased to 42°C and the feed changed to Feed II, below. The fermentation was allowed to continue for 10 hours with sampling every 2 hours. After 10 hours, the contents of the fermentor was chilled to below 20°C and harvested by centrifugation.

Media Composition:		
	Batch:	
5	Feed I:	10 g/L Yeast extract
		5.25 g/L $(\text{NH}_4)_2\text{SO}_4$
		3.5 g/L $\text{K}_2\text{HPO}_4$
		4.0 g/L $\text{KH}_2\text{PO}_4$
		5.0 g/L Glucose
		1.0 g/L $\text{MgSO}_4 \cdot 7\text{H}_2\text{O}$
		2.0 mL/L Vitamin Solution
		2.0 mL/L Trace Metal Solution
		1.0 mL/L P2000 Antifoam
		50 g/L Bacto-tryptone
10	Feed II:	50 g/L Yeast extract
		450 g/L Glucose
		8.75 g/L $\text{MgSO}_4 \cdot 7\text{H}_2\text{O}$
		10 mL/L Vitamin Solution
		10 mL/L Trace Metal Solution
		200 g/L Bacto-tryptone
		100 g/L Yeast extract
		110 g/L Glucose
15		
20		
25		
30		

**Vitamin Solution (Batch and Feed I):**

35 [0083] 0.5 g Biotin, 0.4 g Folic acid, and 4.2 g riboflavin, was dissolved in 450 mls  $\text{H}_2\text{O}$  and 3 mls 10 N NaOH, and brought to 500 mLs in  $\text{H}_2\text{O}$ . 14 g pyridoxine-HCl and 61 g niacin was dissolved 150 mL  $\text{H}_2\text{O}$  and 50 mL 10 N NaOH, and brought to 250 mL in  $\text{H}_2\text{O}$ . 54 g pantothenic acid was dissolved in 200 mL  $\text{H}_2\text{O}$ , and brought to 250 mL. The three solutions were combined and brought to 10 liters total volume.

**40 Trace Metal Solution (Batch and Feed I):****[0084]**

45 Ferric Chloride ( $\text{FeCl}_3 \cdot 6\text{H}_2\text{O}$ ): 27 g/L  
 Zinc Chloride ( $\text{ZnCl}_2 \cdot 4\text{H}_2\text{O}$ ): 2 g/L  
 Cobalt Chloride ( $\text{CoCl}_2 \cdot 6\text{H}_2\text{O}$ ): 2 g/L  
 Sodium Molybdate ( $\text{NaMoO}_4 \cdot 2\text{H}_2\text{O}$ ): 2 g/L  
 Calcium Chloride ( $\text{CaCl}_2 \cdot 2\text{H}_2\text{O}$ ): 1 g/L  
 Cupric Sulphate ( $\text{CuSO}_4 \cdot 5\text{H}_2\text{O}$ ): 1.9 g/L  
 50 Boric Acid ( $\text{H}_3\text{BO}_3$ ): 0.5 g/L  
 Manganese Chloride ( $\text{MnCl}_2 \cdot 4\text{H}_2\text{O}$ ): 1.6 g/L  
 Sodium Citrate dihydrate: 73.5 g/L

**Purification Process for Murine OB Protein**

55 [0085] Purification was accomplished by the following steps (unless otherwise noted, the following steps were performed at 4°C):

1. Cell paste. *E. coli* cell paste was suspended in 5 times volume of 7 mM of EDTA, pH 7.0. The cells in the EDTA were further broken by two passes through a microfluidizer. The broken cells were centrifuged at 4.2 K rpm for 1 hour in a Beckman J6-B centrifuge with a JS-4.2 rotor.
- 5       2. Inclusion body wash #1. The supernatant from above was removed, and the pellet was resuspended with 5 times volume of 7 mM EDTA, pH 7.0, and homogenized. This mixture was centrifuged as in step 1.
- 10      3. Inclusion body wash #2. The supernatant from above was removed, and the pellet was resuspended in ten times volume of 20 mM tris, pH 8.5, 10 mM DTT, and 1% deoxycholate, and homogenized. This mixture was centrifuged as in step 1.
- 15      4. Inclusion body wash #3. The supernatant from above was removed and the pellet was resuspended in ten times volume of distilled water, and homogenized. This mixture was centrifuged as in step 1.
- 20      5. Refolding. The pellet was refolded with 15 volumes of 10 mM HEPES, pH 8.5, 1% sodium sarcosine (N-lauroyl sarcosine), at room temperature. After 60 minutes, the solution was made to be 60 µm copper sulfate, and then stirred overnight.
- 25      6. Removal of sarcosine. The refolding mixture was diluted with 5 volumes of 10 mM tris buffer, pH 7.5, and centrifuged as in step 1. The supernatant was collected, and mixed with agitation for one hour with Dowex® 1-X4 resin (Dow Chemical Co., Midland MI), 20-50 mesh, chloride form, at 0.066% total volume of diluted refolding mix. See WO 89/10932 at page 26 for more information on Dowex®. This mixture was poured into a column and the eluant collected. Removal of sarcosine was ascertained by reverse phase HPLC.
- 30      7. Acid precipitation. The eluant from the previous step was collected, and pH adjusted to pH 5.5, and incubated for 30 minutes at room temperature. This mixture was centrifuged as in step 1.
- 35      8. Cation exchange chromatography. The pH of the supernatant from the previous step was adjusted to pH 4.2, and loaded on CM Sepharose Fast Flow (at 7% volume). 20 column volumes of salt gradient were done at 20 mM NaOAC, pH 4.2, 0 M to 1.0 M NaCl.
9. Hydrophobic interaction chromatography. The CM Sepharose pool of peak fractions (ascertained from ultraviolet absorbance) from the above step was made to be 0.2 M ammonium sulfate. A 20 column volume reverse salt gradient was done at 5 mM NaOAC, pH 4.2, with .4 M to 0 M ammonium sulfate. This material was concentrated and diafiltered into PBS.
- [0086] Fermentation of recombinant human OB protein analog: Fermentation of the above host cells to produce recombinant human OB protein analog (SEQ. ID. NO. 4) can be accomplished using the conditions and compositions as described above for recombinant murine material.
- [0087] Purification of the recombinant human OB protein analog: Recombinant human protein analog may be purified using methods similar to those used for purification of recombinant murine protein, as in Example 1, above. For preparation of recombinant human OB protein analog, step 8 should be performed by adjusting the pH of the supernatant from step 7 to pH 5.0, and loading this onto a CM Sepharose fast flow column. The 20 column volume salt gradient should be performed at 20 mM NaOAC, pH 5.5, 0M to 0.5 M NaCl. Step 9 should be performed by diluting the CM Sepharose pool four fold with water, and adjusting the pH to 7.5. This mixture should be made to 0.7 M ammonium sulfate. Twenty column volume reverse salt gradient should be done at 5 mM NaOAC, pH 5.5, 0.2 M to 0M ammonium sulfate. Otherwise, the above steps are identical. For EXAMPLE 2 material, the recombinant human OB protein of SEQ.ID.NO.4 having lysine 35 and isoleucine 74 was formulated in a buffer containing 10 mM histidine, 4.3% arginine, at pH 6.0.
- [0088] While the present invention has been described in terms of preferred embodiments, it is understood that variations and modifications will occur to those skilled in the art. Therefore, it is intended that the appended claims cover all such equivalent variations which come within the scope of the invention as claimed.

FEATURES

55

[0089]

1. A method for increasing lean tissue mass, comprised of administering an effective amount of an OB protein, ana-

log or derivative thereof selected from among:

- (a) the amino acid sequence 1-146 as set forth in SEQ. ID. NO. 2 or SEQ ID. NO. 4;
- (b) the amino acid sequence 1-146 as set forth in SEQ. ID. NO. 4 having a lysine residue at position 35 and an isoleucine residue at position 74;
- (c) the amino acid sequence of subpart (b) having a different amino acid substituted in one or more of the following positions (using the numbering according to SEQ. ID. NO. 4): 4, 8, 32, 33, 35, 48, 50, 53, 60, 64, 66, 67, 68, 71, 74, 77, 78, 89, 97, 100, 102, 105, 106, 107, 108, 111, 112, 118, 136, 138, 142, and 145;
- (d) the amino acid sequence of subparts (a), (b) or (c) optionally lacking a glutamyl residue at position 28;
- (e) the amino acid sequence of subparts (a), (b), (c), or (d) having a methionyl residue at the N terminus.
- (f) a truncated OB protein analog selected from among: (using the numbering of SEQ. ID. NO. 4 having a lysine residue at position 35, and an isoleucine residue at position 74):
  - (i) amino acids 98-146
  - (ii) amino acids 1-32
  - (iii) amino acids 40-116
  - (iv) amino acids 1-99 and 112-146
  - (v) amino acids 1-99 and 112-146 having one or more of amino acids 100-111 sequentially placed between amino acids 99 and 112; and,
  - (vi) the truncated OB analog of subpart (f) (i) having one or more of amino acids 100, 102, 105, 106, 107, 108, 111, 112, 118, 136, 138, 142, and 145 substituted with another amino acid;
  - (vii) the truncated analog of subpart (f) (ii) having one or more of amino acids 4, 8 and 32 substituted with another amino acid;
  - (viii) the truncated analog of subpart (f) (iii) having one or more of amino acids 50, 53, 60, 64, 66, 67, 68, 71, 74, 77, 78, 89, 97, 100, 102, 105, 106, 107, 108, 111 and 112 replaced with another amino acid;
  - (ix) the truncated analog of subpart (f) (iv) having one or more of amino acids 4, 8, 32, 33, 35, 48, 50, 53, 60, 64, 66, 67, 68, 71, 74, 77, 78, 89, 97, 100, 102, 105, 106, 107, 108, 111, 112, 118, 136, 138, 142, and 145 replaced with another amino acid;
  - (x) the truncated analog of subpart (f) (v) having one or more of amino acids 4, 8, 32, 33, 35, 48, 50, 53, 60, 64, 66, 67, 68, 71, 74, 77, 78, 89, 97, 100, 102, 105, 106, 107, 108, 111, 112, 118, 136, 138, 142, and 145 replaced with another amino acid;
  - (xi) the truncated analog of any of subparts (f) (i)-(x) having an N-terminal methionyl residue; and
- (g) the OB protein or analog derivative of any of subparts (a) through (f) comprised of a chemical moiety connected to the protein moiety;
- (h) a derivative of subpart (g) wherein said chemical moiety is a water soluble polymer moiety;
- (i) a derivative of subpart (h) wherein said water soluble polymer moiety is polyethylene glycol;
- (j) A derivative of subpart (h) wherein said water soluble polymer moiety is a polyamino acid moiety;
- (k) a derivative of subpart (h) wherein said water soluble polymer moiety is attached at solely the N-terminus of said protein moiety;
- (l) an OB protein, analog or derivative of any subparts (a) through (k) in a pharmaceutically acceptable carrier.

2. A method of feature 1 wherein said method also provides for an increased sensitivity to insulin.

45 3. A method of feature 1 wherein said method also provides for an increase in overall body strength.

4. A method of feature 1 wherein said method also provides for decreased bone resorption.

50

55

## SEQUENCE LISTING

## 5 (1) GENERAL INFORMATION:

(i) APPLICANT: Amgen Inc.

(ii) TITLE OF INVENTION: METHODS OF INCREASING LEAN TISSUE MASS  
USING OB PROTEIN COMPOSITIONS

10 (iii) NUMBER OF SEQUENCES: 6

## (iv) CORRESPONDENCE ADDRESS:

- (A) ADDRESSEE: AMGEN INC.
- (B) STREET: 1840 Dehavilland Drive
- (C) CITY: Thousand Oaks
- (D) STATE: California
- (E) COUNTRY: U.S.A.
- (F) ZIP: 91320-1789

## 20 (v) COMPUTER READABLE FORM:

- (A) MEDIUM TYPE: Floppy disk
- (B) COMPUTER: IBM PC compatible
- (C) OPERATING SYSTEM: PC-DOS/MS-DOS
- (D) SOFTWARE: PatentIn Release #1.0, Version #1.30

## 25 (vi) CURRENT APPLICATION DATA:

- (A) APPLICATION NUMBER:
- (B) FILING DATE:
- (C) CLASSIFICATION:

## 30 (viii) ATTORNEY/AGENT INFORMATION:

- (A) NAME: Pessin, Karol M.
- (C) REFERENCE/DOCKET NUMBER: A-376

## 35 (2) INFORMATION FOR SEQ ID NO:1:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 491 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

40 (ii) MOLECULE TYPE: DNA (genomic)

## 45 (ix) FEATURE:

- (A) NAME/KEY: CDS
- (B) LOCATION: 41..481

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

TCTAGATTTG AGTTTTAACT TTTAGAAGGA GGAATAACAT ATG GTA CCG ATC CAG  
 Met Val Pro Ile Gln  
 1 5

55

	AAA GTT CAG GAC GAC ACC AAA ACC TTA ATT AAA ACG ATC GTT ACG CGT Lys Val Gln Asp Asp Thr Lys Thr Leu Ile Lys Thr Ile Val Thr Arg 10 15 20	103
5	ATC AAC GAC ATC AGT CAC ACC CAG TCG GTC TCC GCT AAA CAG CGT GTT Ile Asn Asp Ile Ser His Thr Gln Ser Val Ser Ala Lys Gln Arg Val 25 30 35	151
10	ACC GGT CTG GAC TTC ATC CCG GGT CTG CAC CCG ATC CTA AGC TTG TCC Thr Gly Leu Asp Phe Ile Pro Gly Leu His Pro Ile Leu Ser Leu Ser 40 45 50	199
15	AAA ATG GAC CAG ACC CTG GCT GTA TAC CAG CAG GTG TTA ACC TCC CTG Lys Met Asp Gln Thr Leu Ala Val Tyr Gln Gln Val Leu Thr Ser Leu 55 60 65	247
20	CCG TCC CAG AAC GTT CTT CAG ATC GCT AAC GAC CTC GAG AAC CTT CGC Pro Ser Gln Asn Val Leu Gln Ile Ala Asn Asp Leu Glu Asn Leu Arg 70 75 80 85	295
25	GAC CTG CTG CAC CTG CTG GCA TTC TCC AAA TCC TGC TCC CTG CCG CAG Asp Leu Leu His Leu Leu Ala Phe Ser Lys Ser Cys Ser Leu Pro Gln 90 95 100	343
30	ACC TCA GGT CTT CAG AAA CCG GAA TCC CTG GAC GGG GTC CTG GAA GCA Thr Ser Gly Leu Gln Lys Pro Glu Ser Leu Asp Gly Val Leu Glu Ala 105 110 115	391
35	TCC CTG TAC ACC ACC GAA GTT GTT GCT CTG TCC CGT CTG CAG GGT TCC Ser Leu Tyr Ser Thr Glu Val Val Ala Leu Ser Arg Leu Gln Gly Ser 120 125 130	439
40	CTT CAG GAC ATC CTT CAG CAG CTG GAC GTT TCT CCG GAA TGT Leu Gln Asp Ile Leu Gln Gln Leu Asp Val Ser Pro Glu Cys 135 140 145	481
45	TAATGGATCC	491

## (2) INFORMATION FOR SEQ ID NO:2:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 147 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: protein

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

Met Val Pro Ile Gln Lys Val Gln Asp Asp Thr Lys Thr Leu Ile Lys 1 5 10 15
50 Thr Ile Val Thr Arg Ile Asn Asp Ile Ser His Thr Gln Ser Val Ser 20 25 30

Ala Lys Gln Arg Val Thr Gly Leu Asp Phe Ile Pro Gly Leu His Pro  
 35 40 45

5 Ile Leu Ser Leu Ser Lys Met Asp Gln Thr Leu Ala Val Tyr Gln Gln  
 50 55 60

Val Leu Thr Ser Leu Pro Ser Gln Asn Val Leu Gln Ile Ala Asn Asp  
 65 70 75 80

10 Leu Glu Asn Leu Arg Asp Leu Leu His Leu Leu Ala Phe Ser Lys Ser  
 85 90 95

Cys Ser Leu Pro Gln Thr Ser Gly Leu Gln Lys Pro Glu Ser Leu Asp  
 100 105 110

15 Gly Val Leu Glu Ala Ser Leu Tyr Ser Thr Glu Val Val Ala Leu Ser  
 115 120 125

20 Arg Leu Gln Gly Ser Leu Gln Asp Ile Leu Gln Gln Leu Asp Val Ser  
 130 135 140

Pro Glu Cys  
 145

(2) INFORMATION FOR SEQ ID NO:3:

25 (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 454 base pairs  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: double  
 (D) TOPOLOGY: linear

30 (ii) MOLECULE TYPE: DNA (genomic)

(ix) FEATURE:  
 (A) NAME/KEY: CDS  
 35 (B) LOCATION: 4..444

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

40 CAT ATG GTA CCG ATC CAG AAA GTT CAG GAC ACC AAA ACC TTA ATT 48  
 Met Val Pro Ile Gln Lys Val Gln Asp Asp Thr Lys Thr Leu Ile  
 1 5 10 15

45 AAA ACG ATC GTT ACG CGT ATC AAC GAC ATC AGT CAC ACC CAG TCG GTG 96  
 Lys Thr Ile Val Thr Arg Ile Asn Asp Ile Ser His Thr Gln Ser Val  
 20 25 30

AGC TCT AAA CAG CGT GTT ACA GCC CTG GAC TTC ATC CCG GGT CTG CAC 144  
 Ser Ser Lys Gln Arg Val Thr Gly Leu Asp Phe Ile Pro Gly Leu His  
 35 40 45

50 CCG ATC CTG ACC TTG TCC AAA ATG GAC CAG ACC CTG GCT GTA TAC CAG 192  
 Pro Ile Leu Thr Leu Ser Lys Met Asp Gln Thr Leu Ala Val Tyr Gln  
 50 55 60

5 CAG ATC TTA ACC TCC ATG CCG TCC CGT AAC GTT CTT CAG ATC TCT AAC 240  
 Gln Ile Leu Thr Ser Met Pro Ser Arg Asn Val Leu Gln Ile Ser Asn  
 65 70 75

10 GAC CTC GAG AAC CTT CGC GAC CTG CTG CAC GTG CTG GCA TTC TCC AAA 288  
 Asp Leu Glu Asn Leu Arg Asp Leu Leu His Val Leu Ala Phe Ser Lys  
 80 85 90 95

15 TCC TGC CAC CTG CCA TGG GCT TCA GGT CTT GAG ACT CTG GAC TCT CTG 336  
 Ser Cys His Leu Pro Trp Ala Ser Gly Leu Glu Thr Leu Asp Ser Leu  
 100 105 110

20 GGC GGG GTC CTG GAA GCA TCC GGT TAC AGC ACC GAA GTT GTT GCT CTG 384  
 Gly Gly Val Leu Glu Ala Ser Gly Tyr Ser Thr Glu Val Val Ala Leu  
 115 120 125

25 TCC CGT CTG CAG GGT TCC CTT CAG GAC ATG CTT TGG CAG CTG GAC CTG 432  
 Ser Arg Leu Gln Gly Ser Leu Gln Asp Met Leu Trp Gln Leu Asp Leu  
 130 135 140

30 TCT CCG GGT TGT TAATGGATCC 454  
 Ser Pro Gly Cys  
 145

35 (2) INFORMATION FOR SEQ ID NO:4:  
 (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 147 amino acids  
 (B) TYPE: amino acid  
 (D) TOPOLOGY: linear

40 (ii) MOLECULE TYPE: protein  
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:  
 Met Val Pro Ile Gln Lys Val Gln Asp Asp Thr Lys Thr Leu Ile Lys 55  
 1 5 10 15

45 Thr Ile Val Thr Arg Ile Asn Asp Ile Ser His Thr Gln Ser Val Ser 30  
 20 25 30

50 Ser Lys Gln Arg Val Thr Gly Leu Asp Phe Ile Pro Gly Leu His Pro 45  
 35 40 45

55 Ile Leu Thr Leu Ser Lys Met Asp Gln Thr Leu Ala Val Tyr Gln Gln 60  
 50 55 60

60 Ile Leu Thr Ser Met Pro Ser Arg Asn Val Leu Gln Ile Ser Asn Asp 80  
 65 70 75 80

65 Leu Glu Asn Leu Arg Asp Leu Leu His Val Leu Ala Phe Ser Lys Ser 95  
 85 90 95

70 Cys His Leu Pro Trp Ala Ser Gly Leu Glu Thr Leu Asp Ser Leu Gly 110  
 100 105 110

Gly Val Leu Glu Ala Ser Gly Tyr Ser Thr Glu Val Val Ala Leu Ser  
 115 120 125

5 Arg Leu Gln Gly Ser Leu Gln Asp Met Leu Trp Gln Leu Asp Leu Ser  
 130 135 140

10 Pro Gly Cys  
 145

15 (2) INFORMATION FOR SEQ ID NO:5:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 491 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: double
  - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA (genomic)

20 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

GGATCCATTAA	ACATTCCGGA	GAAACGTCCA	CCTGCTGAAG	GATGTCCTGA	AGGGAACCCCT	60
GCAGACGGGA	CAGAGCAACA	ACTTCGGTCC	TGTACAGGGGA	TGCTTCCAGG	ACCCCGAGGT	120
CGCGAAGGTT	CTCGAGGTCTG	TTAGCGATCT	GAAGAACGTT	CTGGGACGGC	AGGGAGGTTA	180
30 ACACCTGCTG	GAGGTCCGGA	AGGTTCTCGA	GGTCGTTAGC	GATCTGAAGA	ACGTTCTGGG	240
ACGGCAGGGGA	GGTTAACACC	TGCTGGTATC	AGACCAGGGT	CTGGTCCATT	TTGGCAAAGC	300
TTAGGATCGG	GTGCAGACCC	GGGATGAAGT	CCAGACCGGT	AACACGCTGT	TTAGCGGAGA	360
35 CCGACTGGGT	GTGACTGATG	TCGTTGATAC	GGTAACCGAT	CGTTTAATT	AAGGTTGTTG	420
TGTCGTCCTG	AACTTCTGG	ATCGGTACCA	TATGTTATTC	CTCCTTCTAA	AAGTTAAAAC	480
TCAAATCTAG A						491

40 (2) INFORMATION FOR SEQ ID NO:6:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 453 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: double
  - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA (genomic)

50 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

5	GGATCCATTA ACAACCCGGA GACAGGTCCA GCTGCCAAGC ATGTCCTAAG GGAACCCTGC	60
	AGACGGGACA GAGCAACAAC TTCGGTTGCT GTAAACCGGAT GCTTCCAGGA CCCCAGCCAG	120
	AGAGTCCAGA GTCTCAAGAC CTGAAGCCCA TGGCAGGTGG CAGGATTGG AGAATGCCAG	180
10	CACGTGCAGC AGGTCGCGAA GGTTCTCGAG GTCGTTAGAG ATCTGAAGAA CGTTACGGGA	240
	CGGCATGGAG GTTAAGATCT GCTGGTATAAC AGCCAGGGTC TGGTCCATTT TGGACAAGGT	300
	CAGGATCGGG TGCAGACCCG GGATGAAGTC CAGGCCTGTA ACACGCTGTT TAGAGCTCAC	360
15	CGACTGGGTG TGACTGATGT CGTTGATAACG CGTAACGATC GTTTAATTA AGGTTTGTT	420
	GTCGTCTGAA ACTTTCTGGA TCGGTACCAT ATG	453

20

## Claims

- 25 1. A fusion protein comprising a Fe protein fused to the N-terminus of an OB protein, analog or derivative.
2. A fusion protein according to Claim 1, wherein the OB protein, analog or derivative is selected from
- (a) the amino acid sequence 1-146 as set forth in SEQ. ID. NO. 2 or SEQ. ID. NO. 4;
  - 30 (b) the amino acid sequence 1-146 as set forth in SEQ. ID. NO. 4 having a lysine residue at position 35 and an isoleucine residue at position 74;
  - (c) the amino acid sequence of subpart (b) having a different amino acid substituted in one or more of the following positions (using the numbering according to SEQ. ID. NO. 4) : 4, 8, 32, 33, 35, 48, 50, 53, 60, 64, 66, 67, 68, 71, 74, 77, 78, 89, 97, 100, 102, 105, 106, 107, 108, 111, 112, 118, 136, 138, 142 and 145;
  - 35 (d) the amino acid sequence of subparts (a), (b) or (c) optionally lacking a glutamyl residue at position 28;
  - (e) the amino acid sequence of subparts (a), (b), (c), or (d) having a methionyl residue at the N terminus.
  - (f) a truncated OB protein analog selected from among: (using the numbering of SEQ. ID. NO. 4 having a lysine residue at position 35, and an isoleucine residue at position 74):
- 40 (i) amino acids 98-146
- (ii) amino acids 1-32
- (iii) amino acids 40-116
- (iv) amino acids 1-99 and 112-146
- (v) amino acids 1-99 and 112-146 having one or more of amino acids 100-111 sequentially placed between amino acids 99 and 112; and,
- 45 (vi) the truncated OB analog of subpart (f) (i) having one or more of amino acids 100, 102, 105, 106, 107, 108, 111, 112, 118, 136, 138, 142, and 145 substituted with another amino acid;
- (vii) the truncated analog of subpart (f) (ii) having one or more of amino acids 4, 8 and 32 substituted with another amino acid;
- 50 (viii) the truncated analog of subpart (f) (iii) having one or more of amino acids 50, 53, 60, 64, 66, 67, 68, 71, 74, 77, 78, 89, 97, 100, 102, 105, 106, 107, 108, 111 and 112 replaced with another amino acid;
- (ix) the truncated analog of subpart (f) (iv) having one or more of amino acids 4, 8, 32, 33, 35, 38, 50, 53, 60, 64, 66, 67, 68, 71, 74, 77, 78, 89, 97, 100, 102, 105, 106, 107, 108, 111, 112, 118, 136, 138, 142, and 145 replaced with another amino acid;
- 55 (x) the truncated analog of subpart (f) (v) having one or more of amino acids 4, 8, 32, 33, 35, 38, 50, 53, 60, 64, 66, 67, 68, 71, 74, 77, 78, 89, 97, 100, 102, 105, 106, 107, 108, 111, 112, 118, 136, 138, 142, and 145 replaced with another amino acid;
- (xi) the truncated analog of any of subparts (f) (i) - (x) having an N-terminal methionyl residue.



## EUROPEAN SEARCH REPORT

Application Number  
EP 98 11 9160

DOCUMENTS CONSIDERED TO BE RELEVANT			CLASSIFICATION OF THE APPLICATION (Int.Cl.)						
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim							
A	WO 95 05309 A (PUTZMEISTER MASCHF ;WANNER MARTIN (DE); HERKOMMER THOMAS FRED (DE)) 23 February 1995 (1995-02-23) * page 88, line 6 - line 16; claims; examples *	1	A61K38/22 C07K14/575						
A	YIYING ZHANG ET AL: "POSITIONAL CLONING OF THE MOUSE OBESE GENE AND ITS HUMAN HOMOLOGUE" NATURE, vol. 372, no. 6505, 1 December 1994 (1994-12-01), pages 425-432, XP000602062 * page 431, left-hand column, paragraph 2 - right-hand column, last paragraph *	1							
A	EP 0 362 999 A (BUNGE AUSTRALIA) 11 April 1990 (1990-04-11) * page 2, line 8 - line 12 * * page 3, line 46 - line 50; claims; examples *	1							
A	EP 0 306 673 A (ENIRICERCHE SPA) 15 March 1989 (1989-03-15) * page 2, line 14 - line 15; claims; examples *	1	A61K C07K						
A	WO 91 11111 A (UNIV IOWA RES FOUND) 8 August 1991 (1991-08-08) * page 4, paragraph 2 - page 5, paragraph 1; claims; examples *	1							
E	WO 97 00319 A (SMITHKLINE BEECHAM PLC ;BROWNE MICHAEL JOSEPH (GB); CHAPMAN CONRAD) 3 January 1997 (1997-01-03) * page 6, line 1 - line 7 * * page 7, line 15 - page 14, line 21; claims; examples *	1,2 -/-							
<p>The present search report has been drawn up for all claims</p> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 33%;">Place of search</td> <td style="width: 33%;">Date of completion of the search</td> <td style="width: 33%;">Examiner</td> </tr> <tr> <td>THE HAGUE</td> <td>8 September 1999</td> <td>Fuhr, C</td> </tr> </table>				Place of search	Date of completion of the search	Examiner	THE HAGUE	8 September 1999	Fuhr, C
Place of search	Date of completion of the search	Examiner							
THE HAGUE	8 September 1999	Fuhr, C							
CATEGORY OF CITED DOCUMENTS		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document							
X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document									



European Patent  
Office

## EUROPEAN SEARCH REPORT

Application Number  
EP 98 11 9160

DOCUMENTS CONSIDERED TO BE RELEVANT									
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.6)						
E	WO 97 24440 A (GENENTECH INC ;SAUVAGE FREDERIC J DE (US); LEVIN NANCY (US); VANDL) 10 July 1997 (1997-07-10) * claims; examples *	1,2							
T	WO 98 28427 A (AMGEN INC) 2 July 1998 (1998-07-02) * page 8, line 18 - page 14, line 4; claims 5,13 *	1,2							
T	WO 98 46257 A (AMGEN INC) 22 October 1998 (1998-10-22) * page 10, line 13 - page 12, line 25 * * page 15, line 28 - page 16, line 21; claims; examples *	1,2							
			TECHNICAL FIELDS SEARCHED (Int.Cl.6)						
<p>The present search report has been drawn up for all claims</p> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 33%;">Place of search</td> <td style="width: 33%;">Date of completion of the search</td> <td style="width: 33%;">Examiner</td> </tr> <tr> <td>THE HAGUE</td> <td>8 September 1999</td> <td>Fuhr, C</td> </tr> </table>				Place of search	Date of completion of the search	Examiner	THE HAGUE	8 September 1999	Fuhr, C
Place of search	Date of completion of the search	Examiner							
THE HAGUE	8 September 1999	Fuhr, C							
<p><b>CATEGORY OF CITED DOCUMENTS</b></p> <p>X : particularly relevant if taken alone. Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document</p> <p>T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons B : member of the same patent family, corresponding document</p>									

**ANNEX TO THE EUROPEAN SEARCH REPORT  
ON EUROPEAN PATENT APPLICATION NO.**

EP 98 11 9160

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report.  
The members are as contained in the European Patent Office EDP file on  
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

08-09-1999

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9505309	A	23-02-1995	AU 7535394 A AU 7613394 A DE 4428146 A DE 4428734 A DE 59402247 D DE 59405967 D WO 9505310 A EP 0765271 A EP 0711236 A JP 9503973 T JP 9501373 T US 5833762 A US 5769954 A	14-03-1995 14-03-1995 16-02-1995 23-02-1995 30-04-1997 18-06-1998 23-02-1995 02-04-1997 15-05-1996 22-04-1997 10-02-1997 10-11-1998 23-06-1998
EP 0362999	A	11-04-1990	AT 88354 T AU 618396 B AU 4020389 A CA 1335712 A DK 411389 A JP 2156861 A US 5637566 A	15-05-1993 19-12-1991 01-03-1990 30-05-1995 25-02-1990 15-06-1990 10-06-1997
EP 0306673	A	15-03-1989	IT 1228925 B AT 87654 T DE 3879823 A ES 2053635 T JP 1988640 C JP 2000446 A JP 7004254 B US 5268277 A	10-07-1991 15-04-1993 06-05-1993 01-08-1994 08-11-1995 05-01-1990 25-01-1995 07-12-1993
WO 9111111	A	08-08-1991	US 5028440 A AU 627111 B AU 7338691 A CA 2050572 A,C DE 69101595 D DE 69101595 T EP 0465646 A JP 4506606 T US 5087472 A	02-07-1991 13-08-1992 21-08-1991 31-07-1991 11-05-1994 21-07-1994 15-01-1992 19-11-1992 11-02-1992
WO 9700319	A	03-01-1997	AU 6011096 A CA 2224646 A EP 0832219 A	15-01-1997 03-01-1997 01-04-1998
WO 9724440	A	10-07-1997	AU 1520097 A	28-07-1997

**ANNEX TO THE EUROPEAN SEARCH REPORT  
ON EUROPEAN PATENT APPLICATION NO.**

EP 98 11 9160

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report.  
The members are as contained in the European Patent Office EDP file on  
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

08-09-1999

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO 9724440 A		CA	2238307 A	10-07-1997
		CZ	9802013 A	16-09-1998
		EP	0870026 A	14-10-1998
WO 9828427 A	02-07-1998	AU	5606098 A	17-07-1998
WO 9846257 A	22-10-1998	AU	7132798 A	11-11-1998